SLPSimulations Plus, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap against its own history.
Priced for ~2% a year FCF growth. The price demands less than its three-year revenue growth of 14% a year, expectations look modest.
Cheap vs its own history: P/E 46.3 vs a 73.8 median over 36 quarters (−37% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SLP's price assumes
Simulations Plus, Inc. trades at 46.3× earnings against 45.1× for the median Health Information Services name, more expensive than its own group.
Trailing P/E · Health Information Services median 45.1 · 1.02× the median: the market pays up for this one
- Free cash flow yield
- 6.6%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- +2.0%
Growth the price implies · The price pays for +2.0% free cash flow growth a year for a decade; the business has delivered −2.3% a year over the last three.
Details›
- Healthcare median P/E509 names
- 26.0
- Health Information Services median P/E25 names
- 45.1
- Free cash flow, trailing twelve months
- $25M
- Market capitalisation
- $374M
- 3-year revenue growth
- +14%
- 3-year free cash flow growth
- −2.3%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $16.88 |
| Its own P/E history, median | $29.52 |
| Its own P/E history, upper quartile | $36.33 |
| 52-week range | $11.36 – $20.84 |
| Today | $18.50 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #11 of 20 by RyuScore